683 Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

683 Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-36,444	Closed	-$284K	–	270
2023 Q4	$284K	Buy	+36,444	New	+$125K	0.02%	128
2019 Q4	–	Sell	-42,978	Closed	-$4.46M	–	185
2019 Q3	$4.46M	Hold	42,978	–	–	0.5%	49
2019 Q2	$3.98M	Buy	+42,978	New	+$2.99M	0.36%	58

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

683 Capital Management's SYRS Position: Q1 2024 in Review

683 Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2024, closing a stake of 36,444 shares — an estimated $284K sold.

683 Capital Management first reported a position in SYRS in Q2 2019 and held it in 3 quarters. The position peaked at $4.46M in Q3 2019. 75 funds tracked by Wall St. Rank hold SYRS as of Q1 2024.

683 Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
683 Capital Management sold 36,444 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $284K.
683 Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
683 Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $4.46M in Q3 2019.
75 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.